Predictors of patient response to treatment with EGF receptor inhibitors
AssigneesGenomic Health, Inc., Bristol-Myers Squibb Company
InventorsJoffre B. Baker, Drew Watson, Tara Maddala, Steven Shak, David J. Mauro, Shirin K. Ford
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.
Claims12
A method for predicting a likelihood that a human patient with an epidermal growth factor receptor (EGFR)—expressing colorectal cancer will exhibit a beneficial response to an EGFR inhibitor comprising:
- (a) measuring, in a tumor sample obtained from the patient, a level of an RNA transcript, or its expression product, for each of solute carrier family 26, member 3 (SLC26A3), amphiregulin (AREG), epiregulin (EREG) and dual specificity phosphatase 6 (DUSP6),
- (b) normalizing the level of the RNA transcript, or its expression product, for each of SLC26A3, AREG, EREG, and DUSP6 to obtain a normalized expression level for each of SLC26A3, AREG, EREG, and DUSP6;
- and
- (c) using the normalized expression level to determine the likelihood that the patient will exhibit a beneficial response to an EGFR inhibitor,
- wherein the normalized expression levels of SLC26A3, AREG, and EREG are positively correlated with the likelihood that the patient will exhibit a beneficial response to the EGFR inhibitor, and wherein the normalized expression level of DUSP6 is negatively correlated with the likelihood that the patient will exhibit a beneficial response to the EGFR inhibitor.
Dependencies are inferred from the claim text.